Clinical Chemistry Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 46: 132-a-133-a, 2000;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (5)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Swinkels, D. W.
Right arrow Articles by Boerman, R. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Swinkels, D. W.
Right arrow Articles by Boerman, R. H.
Related Collections
Right arrow Molecular Diagnostics and Genetics
(Clinical Chemistry. 2000;46:132-133.)
© 2000 American Association for Clinical Chemistry, Inc.

Letters

Early Detection of Leptomeningeal Metastasis by PCR Examination of Tumor-derived K-ras DNA in Cerebrospinal Fluid

Dorine W. Swinkels1,a

a Address correspondence to this author at: Department of Clinical Chemistry (CKCL 564), University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands. Fax 31-243541743; e-mail D.Swinkels@CKCL.azn.nl.

Jacques B. de Kok1
Anton Hanselaar2
Karel Lamers1
Rudolf H. Boerman3

Departments of
1 Clinical Chemistry,,
2 Pathology, and
3 Neurology, University Hospital Nijmegen, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands


To the Editor:

Leptomeningeal metastasis (LMM) occurs in 3–8% of all cancer patients. Of the solid tumors, breast cancer, lung cancer, and malignant melanoma are the most common to metastasize to the leptomeninges (1). The prognosis for patients with LMM is poor: most individuals survive a median of only ~4 months. Early diagnosis may improve the clinical response to radiotherapy and (intrathecal) chemotherapy, and may lead to more effective palliation and prolonged survival (1).

Traditionally, a definitive diagnosis of LMM requires cytological detection of malignant cells in the cerebrospinal fluid (CSF). Interpretation is often aided by immunocytochemical techniques. Unfortunately, these CSF samples often contain very few morphologically identifiable malignant cells. In these cases, no definitive diagnosis can be established, leading to "suspicious" or "atypical" diagnoses (1).

Molecular detection of tumor-derived DNA in CSF can potentially improve early and sensitive detection of LMM because no intact cells are required for diagnosis (2)(3). . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
J. B. de Kok, T. J.M. Ruers, G. N.P. van Muijen, A. van Bokhoven, H. L. Willems, and D. W. Swinkels
Real-Time Quantification of Human Telomerase Reverse Transcriptase mRNA in Tumors and Healthy Tissues
Clin. Chem., March 1, 2000; 46(3): 313 - 318.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by the American Association for Clinical Chemistry.